AstraZeneca (LON:AZN)‘s stock had its “buy” rating reissued by equities research analysts at Citigroup in a research report issued on Wednesday.

Other equities research analysts have also issued research reports about the stock. Goldman Sachs Group set a GBX 3,900 ($52.49) target price on shares of AstraZeneca and gave the stock a “sell” rating in a report on Friday, August 18th. Investec upped their target price on shares of AstraZeneca from GBX 4,900 ($65.95) to GBX 5,500 ($74.02) and gave the stock a “buy” rating in a report on Monday, November 6th. Shore Capital reaffirmed a “hold” rating on shares of AstraZeneca in a report on Monday, September 11th. Barclays set a GBX 6,300 ($84.79) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Wednesday, September 13th. Finally, Berenberg Bank set a GBX 5,800 ($78.06) target price on shares of AstraZeneca and gave the stock a “buy” rating in a report on Tuesday, September 19th. Four investment analysts have rated the stock with a sell rating, seven have issued a hold rating and twelve have given a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of GBX 5,169 ($69.57).

Shares of AstraZeneca (LON AZN) opened at GBX 4,935 ($66.42) on Wednesday. AstraZeneca has a fifty-two week low of GBX 4,134.50 ($55.65) and a fifty-two week high of GBX 5,520 ($74.29).

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.watchlistnews.com/astrazeneca-azn-stock-rating-reaffirmed-by-citigroup/1760435.html.

About AstraZeneca

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.